Newborn use only

Alert	1:10,000 (1 mg/10 mL) adrenaline acid tartrate ampoule is the preferred preparation for IV bolus.	
Indication	Resuscitation of the newborn infant.[1]	
Action	Catecholamine with alpha and beta-adrenergic actions.	
Drug type	Inotropic vasopressor	
Trade name	Aspen Adrenaline 1:10,000 Injection, Adrenaline-Link Injection BP 1:10,000 Ampoule, Min-I-Jet Adrenaline 1:10,000 Injection (Pre-filled Syringe).	
Presentation	1:10,000 ampoule [100micrograms/1mL] as adrenaline acid tartrate (Recommended) 1: 10,000 Min-I-Jet pre-filled syringe [100micrograms/1mL] as adrenaline hydrochloride (if ampoules are in short supply)	
Dose	10–30 microgram/kg (0.1–0.3 mL/kg of a 1:10,000 solution) intravenous injection. This dose can be repeated every few minutes if the heart rate remains < 60 beats per minute despite effective ventilation and cardiac compressions.[1-3]	
Dose adjustment	Not applicable.	
Maximum dose		
Total cumulative dose		
Route	Intravenous.	
Preparation	Draw up 10-30 microgram/kg (0.1–0.3 mL/kg of adrenaline from 1:10,000 ampoule [1 mg/10 mL] undiluted. [1 mL contains 0.1 mg (100 microgram) of adrenaline].	
Administration	Intravenous as a rapid bolus ideally through a central venous catheter followed by a sodium chloride 0.9% flush.[1]	
Monitoring	Assessment throughout the resuscitation is based on the infant's heart rate, breathing, tone and oxygenation. A prompt increase in heart rate remains the most sensitive indicator of resuscitation efficacy.[4] For babies requiring resuscitation and/or respiratory support, pulse oximetry is recommended both to monitor heart rate and to assess oxygenation. The sensor should be placed on the infant's right hand or wrist before connecting the probe to the instrument. Heart rate monitored using an oximeter should be checked intermittently during resuscitation by auscultation.[4] Observe IV site closely for blanching and extravasation.	
Contraindications	Nil	
Precautions	Infants with arrhythmias, hypertension or hyperthyroidism. Infants with dilated or ischaemic cardiac disease. Intra-arterial and intramuscular administration should be avoided as it may cause local ischaemic damage. Do not use if the injection is pink or brown or contains a precipitate.	
Drug interactions	Hypotension may be observed with concurrent use of vasodilators such as glyceryl trinitrate, nitroprusside and calcium channel blockers. Concurrent use of digitalis glycosides may increase the risk of cardiac arrhythmias. Concurrent use of IV phenytoin with adrenaline may result in dose dependent, sudden hypotension and bradycardia. Concurrent use of adrenaline and linezolid may result in increased hypertensive effects.	
Adverse reactions	Tachycardia and arrhythmia. Systemic hypertension and lactic acidosis especially at higher doses. Tissue ischaemia and necrosis especially if administered intra-arterially, intramuscularly or with extravasation.	
Compatibility	 Adrenaline acid tartrate (2,3) Fluids: Solutions of adrenaline (epinephrine) acid tartrate in sodium chloride 0.9% or glucose 5% are commonly used in practice despite the lack of compatibility and stability information. Always inspect solutions closely for signs of incompatibility. Glucose 5% is the preferred fluid in critical care settings. Y-site: Giving other drugs via Y-site may change the infusion rate of adrenaline (epinephrine). A dedicated line is preferred. Adrenaline hydrochloride (2,3) Fluids: Glucose 5%, glucose 10%, sodium chloride 0.9%. Y-site: Giving other drugs via Y-site may change the infusion rate of adrenaline (epinephrine). A dedicated line is preferred. Adrenaline hydrochloride (2,3) Fluids: Glucose 5%, glucose 10%, sodium chloride 0.9%. Y-site: Giving other drugs via Y-site may change the infusion rate of adrenaline (epinephrine). A dedicated line is preferred. 	

Newborn use only

I		
	Adrenaline (epinephrine) hydrochloride at 60 microgram/mL (or higher): amikacin, amiodarone, atracurium, cefazolin, cefotaxime, ceftazidime, ceftriaxone, clindamycin, dexamethasone, dobutamine, dopamine, ephedrine sulfate, esmolol, fentanyl, fluconazole, gentamicin, glyceryl trinitrate, heparin sodium, labetalol, lidocaine, magnesium sulfate, methylprednisolone sodium succinate, metoclopramide, midazolam, milrinone, morphine sulfate, phenylephrine, potassium chloride, ranitidine, sodium nitroprusside, tobramycin, verapamil.	
Incompatibility	Fluids (2): No information.	
	Y-site (2): Aciclovir, aminophylline, azathioprine, cefalotin, ganciclovir, hyaluronidase, indometacin, micafungin, phenobarbital, sodium bicarbonate, thiopental.	
	The product information for adrenaline (epinephrine) acid tartrate injection states that it is incompatible with noradrenaline (norepinephrine), however several studies have demonstrated compatibility of adrenaline (epinephrine) hydrochloride and noradrenaline (norepinephrine) at various concentrations.(2)	
Stability	Not for dilution.	
Storage	Store below 25°C. Protect from light.	
Excipients	Aspen Adrenaline: Tartaric acid, sodium metabisulfite, sodium chloride, water for injections. Adrenaline-Link: Sodium metabisulfite, sodium chloride, sodium citrate dihydrate and citric acid monohydrate, water for injections and dilute hydrochloric acid. Min-I-Jet Adrenaline: Water, sulfur dioxide (not more than 0.2% from an equivalent amount of sodium metabisulfite as an antioxidant), sodium chloride, sodium citrate, citric acid monohydrate and hydrochloric acid.	
Spacial commonts		
Special comments	Onset of action is 1 to 2 minutes, duration of effect is short and half-life is 5 minutes.	
Evidence	ILCOR 2020 recommendations: (1) Establishing ventilation is the most important step to correct low heart rate. However, if heart rate remains less than 60 beats/min after optimal ventilation with 100% oxygen (preferably through an endotracheal tube) and chest compressions, it may be reasonable to administer intravascular epinephrine (0.01 to 0.03 mg/kg); (2) While vascular access is being obtained, it may be reasonable to administer endotracheal epinephrine at a larger dose (0.05 to 0.1 mg/kg); (3) If endotracheal epinephrine is given before vascular access is available and response is inadequate, it may be reasonable to give an intravascular (intravenous or intraosseous) dose as soon as access is obtained, regardless of the interval; (4) It may be reasonable to administer further doses of epinephrine every 3 to 5 min, preferably intravascularly, if the heart rate remains less than 60 beats/min.	
Practice points		
References	 Aziz K, Lee HC, Escobedo MB, Hoover AV, Kamath-Rayne BD, Kapadia VS, Magid DJ, Niermeyer S, Schmölzer GM, Szyld E, Weiner GM. Part 5: neonatal resuscitation: 2020 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020 Oct 20;142(16_Suppl_2):S524-50. Australian injectable drugs handbook. Adrenaline (epinephrine). Accessed on 4 May 2021. Micromedex. Epinephrine. Accessed on 4 May 2021. 	

VERSION/NUMBER	DATE
Original	31/03/2016
Revised 2.0	20/05/2021
REVIEW	20/05/2026

Authors Contribution

Original author/s	Srinivas Bolisetty, David Osborn
Current version author/s	Ansar Kunjunju, Eszter Jozsa, Srinivas Bolisetty
Evidence Review	
Expert review	
Nursing Review	Eszter Jozsa, Kirsty Minter
Pharmacy Review	Jessica Mehegan
ANMF Group contributors	Ansar Kunjunju, Nilkant Phad, Bhavesh Mehta, John Sinn, Michelle Jenkins, Thao
	Tran, Helen Huynh, Sarah Woodland, Simarjit Kaur
Final editing and review of the original	lan Whyte

Adrenaline (EPINEPHrine) intravenous bolus Newborn use only

Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty